Fisetin: The Strawberry Flavonoid Investigated as a Senolytic — What Trials Are Underway

Fisetin is a flavonol found in strawberries, apples, persimmons, onions, and cucumbers. It has anti-inflammatory and antioxidant activity in vitro and rodent studies, and since 2018 has been a leading candidate "senolytic" — a drug or compound that selectively kills senescent cells (older, stress-damaged cells thought to drive aging-related disease). The animal data are striking; the human trials are early; the supplement market has run far ahead of either.

What "senolytic" means and why it matters

Senescent cells accumulate with age. They stop dividing but remain metabolically active, secreting a "senescence-associated secretory phenotype" (SASP) of inflammatory cytokines, proteases, and growth factors. SASP is implicated in osteoarthritis, atherosclerosis, type 2 diabetes, frailty, and cognitive decline. In aged mice, periodic senolytic dosing extends median lifespan and improves frailty markers [1].

Why fisetin specifically

A 2018 Mayo Clinic screen tested 10 flavonoids for selective killing of senescent cells in culture. Fisetin was the most potent, outperforming quercetin (a more familiar flavonoid). Aged mice given oral fisetin showed reductions in senescent cell markers in multiple tissues and improvements in median and maximum lifespan [2]. The dose used in mice (about 100 mg/kg) extrapolates to a high human equivalent dose, but most senolytic protocols are designed for short, intermittent "hit and quit" dosing rather than chronic use.

What human trials look like so far

The Mayo Clinic and other groups have launched trials of intermittent high-dose oral fisetin (typically 20 mg/kg/day for two consecutive days, repeated monthly) in older adults with frailty, post-COVID symptoms, chronic kidney disease, and skeletal aging [3]. Most are small (n=20–60), open-label or pilot-phase, and use surrogate endpoints (inflammatory markers, gait speed, biomarkers of senescence). Published results so far have been mixed and preliminary; no large randomised trial with hard endpoints has yet been completed [4].

The bioavailability problem

Standard oral fisetin has poor bioavailability — peak plasma concentrations from 100 mg of unformulated fisetin reach only nanomolar levels, well below the micromolar concentrations effective in cell culture [5]. Liposomal, phytosomal, and nano-formulations claim to improve absorption, but most are unstudied. Whether the doses used in retail supplements (100–500 mg/day chronic) achieve any senolytic activity in human tissues is unclear.

Safety considerations

Short-term toxicity in animals is low, and intermittent dosing in early human trials has been well tolerated. Theoretical concerns include: interaction with chemotherapy and immunotherapy (senescence is a tumour-suppressive mechanism in some contexts); interaction with anticoagulants via flavonoid-mediated platelet effects; and unknown long-term effects of repeatedly killing senescent cells [6].

Practical takeaway

Fisetin is one of the most promising senolytic candidates currently in human trials, but the trials are small, the dose-finding is unsettled, and the long-term safety data are absent. The "anti-aging" supplement market has commercialised fisetin years ahead of clinical evidence. If you are interested in senolytic therapy, the most rational option is participation in a clinical trial. Modest fisetin intake from strawberries and apples is harmless and reasonable. Chronic high-dose self-experimentation outside trials is not supported by current data.

How "senolytic" supplements are being marketed beyond evidence

Several products now combine fisetin with quercetin, dasatinib, spermidine, or rapamycin in "senolytic stacks." None of these combinations has been evaluated in randomised trials in humans for the indications they are sold for (frailty reduction, cognitive preservation, "biological age" reversal). Some pose real interaction risks — quercetin inhibits CYP3A4 and can raise plasma concentrations of statins, calcium channel blockers, and tacrolimus. The single-ingredient research evidence does not yet support the multi-ingredient marketing.

What this means for someone interested in senescence-related health

The most evidence-based interventions for age-related decline remain unsexy: regular resistance and aerobic exercise, adequate protein intake, sleep hygiene, smoking cessation, blood pressure and lipid control. These have demonstrated reductions in frailty, mortality, and cognitive decline in large trials. Senolytic supplementation is a fascinating frontier but should be added to — not substituted for — these basics. Trial participation is the right path for adults motivated by the science.